Verona Pharma plc (VRNA)
VRNA Stock Price Chart
Explore Verona Pharma plc interactive price chart. Choose custom timeframes to analyze VRNA price movements and trends.
VRNA Company Profile
Discover essential business fundamentals and corporate details for Verona Pharma plc (VRNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2017
Employees
209.00
Website
https://www.veronapharma.comCEO
David S. Zaccardelli
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
VRNA Financial Timeline
Browse a chronological timeline of Verona Pharma plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 5 Jan 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.17, while revenue estimate is $86.72M.
Earnings released on 6 Aug 2025
EPS came in at $0.13 surpassing the estimated -$0.01 by +1.40K%.
Earnings released on 29 Apr 2025
EPS came in at $0.27 surpassing the estimated -$0.22 by +222.73%, while revenue for the quarter reached $98.65M , beating expectations by +44.72%.
Earnings released on 27 Feb 2025
EPS came in at -$0.40 falling short of the estimated -$0.23 by -73.91%, while revenue for the quarter reached $45.86M , beating expectations by +73.13%.
Earnings released on 4 Nov 2024
EPS came in at -$0.56 falling short of the estimated -$0.45 by -24.44%, while revenue for the quarter reached $7.53M , missing expectations by -54.88%.
Earnings released on 8 Aug 2024
EPS came in at -$0.88 falling short of the estimated -$0.35 by -151.43%.
Earnings released on 9 May 2024
EPS came in at -$0.32 falling short of the estimated -$0.24 by -33.33%.
Earnings released on 29 Feb 2024
EPS came in at -$0.16 surpassing the estimated -$0.23 by +30.43%, while revenue for the quarter reached $1.19M .
Earnings released on 2 Nov 2023
EPS came in at -$0.18 surpassing the estimated -$0.27 by +33.33%.
Earnings released on 3 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.27 by +59.26%.
Earnings released on 9 May 2023
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%.
Earnings released on 7 Mar 2023
EPS came in at -$0.16 surpassing the estimated -$0.22 by +27.27%, while revenue for the quarter reached $562.91K , missing expectations by -88.74%.
Earnings released on 9 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.30 by +20.00%.
Earnings released on 9 Aug 2022
EPS came in at -$0.32 surpassing the estimated -$0.35 by +8.57%.
Earnings released on 3 May 2022
EPS came in at -$0.40 surpassing the estimated -$0.47 by +14.89%.
Earnings released on 3 Mar 2022
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%.
Earnings released on 9 Nov 2021
EPS came in at $0.17 surpassing the estimated -$0.19 by +189.47%, while revenue for the quarter reached $54.03M , beating expectations by +980.63%.
Earnings released on 5 Aug 2021
EPS came in at -$0.56 falling short of the estimated -$0.39 by -43.59%.
Earnings released on 29 Apr 2021
EPS came in at -$0.55 falling short of the estimated -$0.45 by -22.22%.
Earnings released on 25 Feb 2021
EPS came in at -$0.53 falling short of the estimated -$0.34 by -55.88%.
Earnings released on 29 Oct 2020
EPS came in at -$0.46 falling short of the estimated -$0.21 by -119.05%.
VRNA Stock Performance
Access detailed VRNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.